TheraRadar

Pharma Intelligence, Simplified

Landscape → CNS

Autism Spectrum Disorder

215 clinical trials

86 active
/
215 total (since 2015)
17
Phase 1 Active
53 total
58
Phase 2 Active
128 total
16
Phase 3 Active
44 total
7
Phase 4 Active
17 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Intra-Cellular Therapies, Inc. 4 0 0
Bristol-Myers Squibb 2 0 0
MapLight Therapeutics 2 0 0
Curemark 1 1 0
Vanda Pharmaceuticals 1 1 0
Karuna Therapeutics 1 0 0
Definium Therapeutics US, Inc. 1 0 0
Fenix Innovation Group 1 0 0
Bazelet Nehushtan LtD. 1 0 0
Shanghai Auzone Biological Technology Co., Ltd. 1 0 0
Neuroventi Inc. 1 0 0
Montera Health Texas LLC 1 0 0
Roche 0 5 4
AbbVie 0 3 0
Otsuka Pharmaceutical Development & Commercialization, Inc. 0 3 0
NCT07450443 RECRUITING
Role of the Gut Vascular Barrier and Microbiota in Autism Spectrum Disorders
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta n=90
NCT07424404 NOT YET RECRUITING
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
Karuna Therapeutics n=400
NCT07284745 NOT YET RECRUITING
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
Bristol-Myers Squibb n=176
NCT07285798 NOT YET RECRUITING
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
Bristol-Myers Squibb n=176
NCT05664789 RECRUITING
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
Stanford University n=144
NCT05494398 ENROLLING BY INVITATION
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label
Stanford University n=144
NCT07257939 NOT YET RECRUITING
NTI164 in Autism Spectrum Disorder
Fenix Innovation Group n=98
NCT06706674 RECRUITING
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Intra-Cellular Therapies, Inc. n=174
NCT06229210 RECRUITING
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc. n=500
NCT06690398 RECRUITING
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
Intra-Cellular Therapies, Inc. n=174
NCT02649959 ACTIVE NOT RECRUITING
An Open Label Study of CM-AT for the Treatment of Children With Autism
Curemark n=405
NCT06678685 NOT YET RECRUITING
Spironolactone Improved Children With NCOR Mutations
Qilu Hospital of Shandong University n=3
NCT05268796 RECRUITING
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
Stanford University n=90
NCT05361707 RECRUITING
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
Vanda Pharmaceuticals n=100
NCT06315465 NOT YET RECRUITING
Efficacy of MAD as add-on Therapy in Comparison With Standard of Care in Children With ASD
All India Institute of Medical Sciences n=80
NCT04766177 RECRUITING
Role of Bumetanide in Treatment of Autism
Sherief Abd-Elsalam n=80
NCT03553875 TERMINATED
Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
Massachusetts General Hospital n=25
NCT06333964 COMPLETED
A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children
Astrogen, Inc. n=169
NCT05555615 TERMINATED
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
ACADIA Pharmaceuticals Inc. n=209
NCT04578756 COMPLETED
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
AbbVie n=310
NCT04623398 COMPLETED
Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
Assistance Publique - Hôpitaux de Paris n=22
NCT03204786 COMPLETED
Intranasal Vasopressin Treatment in Children With Autism
Stanford University n=157
NCT05927792 COMPLETED
Efficacy and Mechanism of Repetitive Transcranial Magnetic Stimulation in Children With Autism Spectrum Disorders
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine n=200
NCT04174365 COMPLETED
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=119
NCT05523895 COMPLETED
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
ACADIA Pharmaceuticals Inc. n=237
NCT04725383 TERMINATED
Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
University of Missouri, Kansas City n=1
NCT05439616 COMPLETED
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
AbbVie n=161
NCT05212493 COMPLETED
The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
Assaf-Harofeh Medical Center n=128
NCT03715166 TERMINATED
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
Institut de Recherches Internationales Servier n=211
NCT01972074 COMPLETED
Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
Massachusetts General Hospital n=84
NCT02985749 COMPLETED
A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
Massachusetts General Hospital n=7
NCT04258839 COMPLETED
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148
Otsuka Pharmaceutical Development & Commercialization, Inc. n=95
NCT03197922 COMPLETED
Treatment of Encopresis in Children With Autism Spectrum Disorders
Emory University n=117
NCT03715153 TERMINATED
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
Institut de Recherches Internationales Servier n=211
NCT02410902 COMPLETED
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)
Curemark n=190
NCT03504917 TERMINATED
A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
Hoffmann-La Roche n=322
NCT04233502 WITHDRAWN
Efficacy and Safety of Slenyto for Insomnia in Children With ASD
Neurim Pharmaceuticals Ltd.
NCT03487770 COMPLETED
Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder
Otsuka Beijing Research Institute n=111
NCT03640156 COMPLETED
Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
KU Leuven n=25
NCT03771560 COMPLETED
Folinic Acid in Autism
University of California, San Francisco n=18
NCT02007447 TERMINATED
Oxytocin in Adolescents With Autism Spectrum Disorders
University of Sao Paulo General Hospital n=30
NCT02757066 COMPLETED
Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders
Nobelpharma n=196
NCT02654743 COMPLETED
Open Label of Clinical Trial of Sulforaphane in Children With Autism
University of California, San Francisco n=21
NCT02212275 WITHDRAWN
Cortical Metrics in Intervention Trials With Autism Spectrum Disorders
Duke University

Data: ClinicalTrials.gov